Fresenius SE & Co KGaA
XETRA:FRE

Watchlist Manager
Fresenius SE & Co KGaA Logo
Fresenius SE & Co KGaA
XETRA:FRE
Watchlist
Price: 33.34 EUR -0.33%
Market Cap: 18.8B EUR
Have any thoughts about
Fresenius SE & Co KGaA?
Write Note

Fresenius SE & Co KGaA
Operating Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Fresenius SE & Co KGaA
Operating Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
Fresenius SE & Co KGaA
XETRA:FRE
Operating Income
€1.4B
CAGR 3-Years
-29%
CAGR 5-Years
-21%
CAGR 10-Years
-7%
F
Fresenius Medical Care AG & Co KGaA
XETRA:FME
Operating Income
€1.4B
CAGR 3-Years
-10%
CAGR 5-Years
-8%
CAGR 10-Years
-2%
Vita 34 AG
XETRA:V3V
Operating Income
-€2.1m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
E
Euroeyes International Eye Clinic Ltd
HKEX:1846
Operating Income
HK$193.9m
CAGR 3-Years
21%
CAGR 5-Years
20%
CAGR 10-Years
N/A
Synlab AG
XETRA:SYAB
Operating Income
€104.7m
CAGR 3-Years
-38%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Fresenius Medical Care AG
XMUN:FME
Operating Income
€1.4B
CAGR 3-Years
-10%
CAGR 5-Years
-8%
CAGR 10-Years
-2%
No Stocks Found

Fresenius SE & Co KGaA
Glance View

Market Cap
18.8B EUR
Industry
Health Care

Fresenius SE & Co. KGaA, a titan in the global healthcare sector, traces its origins to a humble pharmacy in Frankfurt, Germany, in 1912. Since then, the company has evolved into a multifaceted healthcare conglomerate, positioning itself prominently in four main divisions: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. Each segment synergizes to form a comprehensive healthcare ecosystem. Fresenius Medical Care, the crown jewel of the group, stands as the world’s leading provider of products and services for individuals with renal diseases. This division, with a focus on dialyzing patients suffering from chronic kidney failure, operates a vast network of dialysis clinics and manufactures dialysis machines and related products that account for a significant portion of its income. Meanwhile, Fresenius Kabi, the pharmaceutical and medical device division, specializes in lifesaving drugs and technologies for critically and chronically ill patients. This division thrives on providing clinical nutrition, infusion therapy, and generics, positioning itself as a critical player in hospitals worldwide. Fresenius Helios is acknowledged as Europe's largest private hospital operator, managing a vast array of healthcare facilities that deliver inpatient and outpatient care, ensuring a steady stream of revenue through diverse healthcare services. Lastly, Fresenius Vamed provides a wide range of services for healthcare facilities, from project development and construction to full operational management, allowing the company to gain financial benefits from turnkey hospital solutions and infrastructure development. Through these concerted efforts, Fresenius SE & Co. KGaA cements its role as a key stakeholder in the global healthcare market, generating substantial revenues while addressing diverse medical needs across the globe.

FRE Intrinsic Value
73.78 EUR
Undervaluation 55%
Intrinsic Value
Price

See Also

What is Fresenius SE & Co KGaA's Operating Income?
Operating Income
1.4B EUR

Based on the financial report for Sep 30, 2024, Fresenius SE & Co KGaA's Operating Income amounts to 1.4B EUR.

What is Fresenius SE & Co KGaA's Operating Income growth rate?
Operating Income CAGR 10Y
-7%

Over the last year, the Operating Income growth was -44%. The average annual Operating Income growth rates for Fresenius SE & Co KGaA have been -29% over the past three years , -21% over the past five years , and -7% over the past ten years .

Back to Top